Authors: Walter Stummer Martin J van den Bent Manfred Westphal
Publish Date: 2011/04/09
Volume: 153, Issue: 6, Pages: 1211-1218
Abstract
Data were reviewed by extent of resection during primary surgery from the ALAGlioma Study fluorescenceguided versus conventional resection the BCNU wafer study BCNU wafer versus placebo and the EORTC Study 26981–22981 radiotherapy versus chemoradiotherapy with temozolomideFor glioblastoma patients in the ALA study median survival was 167 and 118 months for complete versus partial resection respectively P 00001 Survival effects were maintained after correction for differences in age and tumor location For glioblastoma patients who received ≥90 resection in the BCNU wafer study median survival increased for BCNU wafer versus placebo 145 versus 124 months respectively P = 002 but no survival increase was found for 90 resection 117 versus 106 months respectively P = 098 In the EORTC study absolute median gain in survival with chemoradiotherapy versus radiotherapy was greatest for complete resections +41 months P = 00001 compared with partial resections +18 months P = 00001 or biopsies +15 months P = 0088 suggesting surgery enhanced adjuvant treatmentWe would like to thank Dr Roger Stupp for insightful comments on the manuscript We also want to thank Susan Wingeron Michael Raffin and Donna Stefanoni from Nexus Communications Inc North Wales PA for their editorial assistance which was financially supported by Archimedes PharmaWalter Stummer MD PhD has received research funding from Medac GmbH and is a consultant with Medac GmbH Martin J van den Bent MD PhD is a consultant for MSD and is member of the MSD speakersbureau Manfred Westphal MD PhD has received honoraria from Ark Therapeutics and Archimedes Pharma
Keywords: